MoonLake End Period Cash Flow from 2010 to 2024

MLTX Stock  USD 54.43  0.19  0.35%   
MoonLake Immunotherapeuti End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, MoonLake Immunotherapeuti End Period Cash Flow regression line of annual values had r-squared of  0.38 and arithmetic mean of  65,809,118. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
451.2 M
Current Value
473.7 M
Quarterly Volatility
161.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 K, Other Operating Expenses of 34.1 M or Total Operating Expenses of 34.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.28. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
  
Check out the analysis of MoonLake Immunotherapeuti Correlation against competitors.

Latest MoonLake Immunotherapeuti's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of MoonLake Immunotherapeutics over the last few years. It is MoonLake Immunotherapeuti's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

MoonLake End Period Cash Flow Regression Statistics

Arithmetic Mean65,809,118
Geometric Mean4,114,856
Coefficient Of Variation245.24
Mean Deviation105,770,521
Median1,335,924
Standard Deviation161,389,978
Sample Variance26046.7T
Range472.4M
R-Value0.62
Mean Square Error17410T
R-Squared0.38
Significance0.01
Slope22,226,442
Total Sum of Squares364654.2T

MoonLake End Period Cash Flow History

2024473.7 M
2023451.2 M
202239.5 M
2021M

About MoonLake Immunotherapeuti Financial Statements

MoonLake Immunotherapeuti investors use historical fundamental indicators, such as MoonLake Immunotherapeuti's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MoonLake Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow451.2 M473.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.